Please assess the completion status of the following clinical trial:

Trial Title: A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, etc.)~* A male or female between 18 and 39 years of age (inclusive) at the time of consent~* Written informed consent obtained from the subject~* Healthy subjects as established by medical history and clinical examination before entering into the study~* Female subjects of non-childbearing potential (non-childbearing potential is defined as having either a current tubal ligation at least three months prior to enrollment, hysterectomy, ovariectomy, or is post-menopause). See Definition of Terms for adequate contraception.~* Female subjects of childbearing potential may be enrolled in the study, if the subject has:~  * Practiced adequate contraception for 30 days prior to vaccination, and~ * A negative urine pregnancy test on the day of vaccination, and~ * Agreed to continue adequate contraception until two months after completion of the vaccination series~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines/placebo during the period starting 30 days preceding the first dose of study vaccine/placebo and/or planned use during the study period~* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 180 days prior to the first vaccine/placebo dose (for corticosteroids, this will mean prednisone ≥ 20 mg/day or equivalent; inhaled and topical steroids are allowed)~* Planned administration or administration of a vaccine/product not foreseen by the study protocol during the period starting 30 days prior to the first dose of vaccine/placebo until after the visit at Day 56 (if influenza activity warrants vaccination of healthy young adults, influenza vaccination will be encouraged and will not lead to study exclusion)~* Planned administration of any flavivirus vaccine for the entire study duration~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).~* Family history of congenital or hereditary immunodeficiency~* History of, or current auto-immune disease~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine/placebo or related to a study procedure~* Major congenital defects or serious chronic illness~* History of any neurological disorders or seizures~* Acute disease and/or fever (≥37.5°C/99.5°F oral body temperature) at the time of enrollment (a subject with a minor illness, i.e., mild diarrhea, mild upper respiratory infection, etc., without fever, may be enrolled at the discretion of the investigator)~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality,as determined by physical examination or laboratory screening tests~* Administration of immunoglobulins and/or any blood products during the period starting 90 days preceding the first dose of study vaccine/placebo or planned administration during the study period~* History of chronic alcohol consumption and/or drug abuse~* Pregnant or lactating female or female planning to become pregnant or planning to discontinue contraceptive precautions~* A planned move to a location that will prohibit participating in the trial until study end for the participant~* Any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.~* Subject seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV)~* Safety laboratory test results that are outside the acceptable values at screening. The following values are not acceptable:~  * \>110% upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, creatinine, serum urea nitrogen (SUN) and bilirubin (total and direct)~ * \<100% lower limit of normal (LLN) or \> 120% ULN for hemoglobin, hematocrit and platelet count~ * \<75% LLN or \>110% ULN for total white blood cell count (WBC) Note that all screening laboratory results must be either within normal limits (WNL) or no more than Grade l not clinically significant (NCS)~(LLN=lower limit of normal; ULN= upper limit of normal, WNL= within normal limits, NCS= not clinically significant)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- TDENV-PIV alum4 (Type: EXPERIMENTAL): 4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
- TDENV-PIV AS01E1 (Type: EXPERIMENTAL): 1 µg TDENV-PIV with AS01E1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
- TDENV-PIV AS03B1 (Type: EXPERIMENTAL): 1 µg TDENV-PIV with AS03B1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
- TDENV-PIV alum1 (Type: EXPERIMENTAL): 1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).